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Abstract
Numerous founder mutations have been reported in BRCA1 and BRCA2. For genetic
screening of a population with a founder mutation, testing can be targeted to the mutation,
allowing for a more rapid and less expensive test. In addition, more precise estimates of the
prior probability of carrying a mutation and of the likelihood of a mutation carrier developing
cancer should be possible. For a given founder mutation a large number of carriers are
available, so that focused scientific studies of penetrance, expression, and genetic and
environmental modifiers of risk can be performed. Finally, founder populations may be a
powerful resource to localize additional breast cancer susceptibility loci, because of the
reduction in locus heterogeneity.
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Introduction
Ethnic differences in the prevalences of many diseases
have been observed. For example, sickle-cell anemia in
individuals of African descent, Tay–Sachs disease in
Ashkenazi Jews [1], and approximately 30 diseases in
Finland [2] are more prevalent than in other populations. A
likely reason for a preponderance of a disease in a specific
population is a founder effect. Founder effects occur when
a population is established by a small number of people or
when a bottleneck occurs that reduces the population to a
small number. When population expansion occurs, the
mutation in a founder becomes prevalent in a larger pro-
portion of the population. There may also be a selective
advantage to the mutation carrier. By following genetic
relationships over many generations, the significance of
founder effects can be studied. Diamond and Rotter [3]
reviewed studies of the Afrikaner population of South
Africa. In 1652, one founding immigrant carried a gene for
Huntington’s chorea and one brother–sister pair carried a
gene for lipoid proteinosis. The result of founder effects is
that these diseases are more common in South Africa
than in Holland from where the carriers emigrated.
Founder populations can be useful in genetic studies, par-
ticularly for genetic mapping of complex traits. There is
little genetic heterogeneity, so that the majority of individu-
als with disease will carry the same gene mutation.
Linkage disequilibrium between the site of the gene and
close markers will exist, so that shared regions of the
genome cosegregating with disease can be more readily
discerned. As an example, Hirschprung’s disease has
been described in individuals of many different back-
grounds. Using a Mennonite population, in which all
affected individuals could be traced to a single common
ancestral couple, one of the genes for the disease was
localized and subsequently identified [4].
Once founder mutations are identified, researchers are
able to examine prevalence of mutations in different popu-
lations and mutation-specific effects on penetrance andBreast Cancer Research    Vol 2 No 2 Neuhausen
disease phenotype. Possibly, better estimates of risk for
individuals in populations with founder mutations can be
calculated. This editorial focuses on founder populations
in genetic studies of breast cancer.
Prevalence of mutations in BRCA1 and BRCA2
BRCA1 and BRCA2, two genes predisposing to breast
and ovarian cancers, were isolated in 1994 and 1995,
respectively [5,6]. Since that time, researchers have been
screening for mutations in high-risk breast and/or ovarian
cancer families and in population-based samples of
women with these cancers to determine the prevalence
and range of mutations. Over 1300 distinct variants have
been found across all population groups, of which approxi-
mately 700 are identified as causal [7,8]. A number of
these mutations have been identified multiple times [8].
Many of these common mutations have been classified as
founder mutations on the basis of a shared haplotype in
the genomic region containing the gene. Founder muta-
tions for BRCA1 and BRCA2 have been described in
numerous populations (Table 1), as well as across popula-
tions. For example, BRCA1 5382insC has been reported
in individuals of Jewish, Dutch, Lithuanian, Russian, Hun-
garian, Germanic, French, Italian, British, and French–
Canadian ancestry [8]. This suggests that this is a rela-
tively old mutation that has spread through migration.
Relative ages of several founder mutations have been
investigated by examining the distance over which haplo-
types are conserved [9,10]. Based on the general age of a
mutation and historic data on migration and social pat-
terns, the origin and subsequent migration of specific
mutations may be described. Now that a large number of
mutation carriers have been identified the Breast Cancer
Linkage Consortium is undertaking such a study for a set
of founder mutations.
Assessment of risk
Genetic screening
Since the isolation of BRCA1 and BRCA2, genetic testing
for mutations is becoming more common in clinical genetic
practice. Important considerations are who should be offered
predictive testing and when it should be done. In general,
mutations in BRCA1 and BRCA2 are rare, probably
accounting for less than 5% of breast cancers and 10% of
ovarian cancers in the population [11,12]. The frequency of
BRCA1 and BRCA2 mutation carriers in women with breast
and/or ovarian cancer is dependent on the study population,
and is highest in young women with breast cancer who have
a strong family history of breast and/or ovarian cancers. An
essential issue for testing is the probability that an individual,
with breast or ovarian cancer or with a family history of
cancer, will carry a mutation in BRCA1 or BRCA2. Probabil-
ity models have been developed to predict the likelihood of
being a mutation carrier before testing [13–16]. Prior proba-
bilities vary depending on the model used.
For genetic testing, there are several advantages to
knowing the founder mutation(s) in a population. First, a
more accurate estimate of the prior probability of carrying a
mutation should be possible. Second, for mutation detec-
tion, testing can be targeted to the founder mutation, allow-
ing for a more rapid and less expensive test. Third, most of
the mutation detection techniques are unable to detect
large deletions and insertions, so that these types of muta-
tions, which may account for 5–15% of deleterious muta-
tions, would be undetected. If one of these mutations is
Table 1
Examples of BRCA1 and BRCA2 founder mutations
Population Mutation Reference
African–Americans BRCA1 943ins10 [40,41]
BRCA1 M1775R
Ashkenazi Jews BRCA1 185delAG [31,34,38]
BRCA1 5382insC 
BRCA2 6174delT
Belgians BRCA1 IVS5 +3A>G [42]
Dutch BRCA1 2804delAA [17,43]
BRCA1 IVS 21-36del510
BRCA1 IVS 12-1643 del3835
BRCA2 5573insA
Finns BRCA1 3745delT [27]
BRCA1 IVS 11-2 A>G
BRCA2 999del5
BRCA2 IVS23-2A>G
French–Canadians BRCA1 R1443X [39,44]
BRCA2 8765delAG
Germans BRCA1 5382insC [45]
BRCA1 C61G
Icelanders BRCA2 999del5 [28]
Latvians BRCA1 C61G [46]
BRCA1 5382insC
BRCA1 4153delA
Norwegians BRCA1 1675delA [47–49]
BRCA1 1135insA
Russians BRCA1 5382insC [50]
BRCA1 4153delA
Swedes BRCA1 Q563X [51]
BRCA1 3166ins5
BRCA1 1201del11
BRCA1 2594delC
BRCA2 4486delGhttp://breast-cancer-research.com/content/2/2/077
known in the population, however, a technique that detects
it can be used for mutation screening. For instance, there
are two large deletion founder mutations in the Dutch that
would not be detectable with standard techniques [17].
Age-specific penetrance
Once an unaffected mutation carrier is identified, the
question becomes what is the likelihood that she will
develop cancer by a given age (age-specific penetrance).
It is especially difficult to answer, because not all factors
that contribute to the development of cancer are known. A
proportion of individuals who carry mutations will not
develop breast cancer or any other cancer. On the basis
of estimates from population-based studies of women
aged 40 years or younger to estimates from high-inci-
dence breast cancer families of Northern European
descent, the cumulative risk of breast cancer by age 70
years for BRCA1 and BRCA2 mutation carriers is
between 40 and 80% [18–20]. Mutation-specific differ-
ences may also be important. There are regions in BRCA1
and  BRCA2 in which mutations confer higher risks for
developing ovarian cancer: 5¢ of codon 1435 in exon 13
of BRCA1 [21] and a 3.3 kilobase region of exon 11 in
BRCA2 (denoted the Ovarian Cancer Cluster Region)
[22]. It is unclear whether the differences in risk for ovarian
cancer are due to a difference in penetrance of the muta-
tions for breast cancer or ovarian cancer, or both. For
BRCA2, it has been suggested that the breast cancer risk
remains the same, but that the ovarian cancer risk
increases [20]. Expression is also variable [23]. In a popu-
lation with a defined founder mutation(s), more accurate
assessment of the likelihood of developing cancer for a
mutation carrier should be possible.
Founder mutations
BRCA1 and BRCA2
An example of a recurrent, founder mutation is the BRCA2
999del5 mutation in the Icelandic population. No other
BRCA2 mutations have been reported in this population.
The 999del5 is approximately 20 times more prevalent
(0.6%) [24] than the estimated allele frequency of BRCA2
in the general worldwide Caucasian population [25]. This
mutation with the same haplotype was also found in
Finland [26,27]. In Iceland, it was the cause of female
breast cancer in the majority (76%) of 21 high-risk breast
cancer families studied [28]. In nine of those 16 families,
male breast cancer was also present [28]. In 632 Ice-
landic breast cancer cases unselected for a family history,
7.7% of female breast cancer diagnosed at any age and
24% of those diagnosed at age 40 years or younger
carried the BRCA2 999del5 mutation [24]. This mutation
is also responsible for a proportion of prostate cancer, as
it accounted for 3.1% (in two out of 65 individuals) of
prostate cancer cases in a population-based series of
cases [29]. Because this is the only BRCA2 mutation
found in Iceland, genetic testing can be targeted to this
mutation. Second, because there are a large number of
individuals, both symptomatic and asymptomatic, who
carry this mutation, it may be possible to develop more
accurate risk estimates for mutation carriers. Age-specific
penetrance has been calculated to be 17% by age 50
years and 37.2% by age 70 years [30]. This is a lower fre-
quency than that reported in other studies of BRCA1 and
BRCA2 penetrance.
Three founder mutations have been observed in Ashkenazi
Jewish breast and ovarian cancer patients. The BRCA2
6174delT mutation has been seen only in Ashkenazi Jews
[31], with a frequency of 0.9–1.5% [32,33]. The founder
BRCA1 185delAG mutation, with a frequency of
0.8–1.1% in Ashkenazi Jews [32,34], is also observed in
Sephardic Jews, indicating an older origin. The 185delAG
mutation has also been observed in individuals of English
origin but on a different haplotype, which suggests a dif-
ferent origin. The third founder mutation, BRCA1
5382insC, has a frequency of 0.13–0.3% in Ashkenazi
Jews. The 5382insC mutation is observed in many popula-
tions, and the vast majority of carriers share the same core
haplotype (Szabo C, personal communication). The popu-
lation prevalences for these three mutations combined is
2–2.5% [32–34], which is approximately 10–50 times
higher than the allele frequency in the general population.
Few other BRCA1 or BRCA2 mutations have been identi-
fied in Jewish breast or ovarian cancer cases. In this popu-
lation, approximately 30% of breast cancers diagnosed at
less than 40 years of age and 39% of ovarian cancers
diagnosed at less than 50 years of age are caused by
these mutations [35,36]. Thus, Ashkenazi Jewish women
with breast or ovarian cancers have a much higher proba-
bility than non-Jewish women of being BRCA1 or BRCA2
mutation carriers. Because these mutations are so
common in Ashkenazi Jewish women, they are commonly
tested as a panel, regardless of whether a mutation has
already been identified in a family member. A woman may
carry a second mutation not present in the first family
member tested and, by testing the panel, it is detected.
Without knowledge of the founder mutations, a false-neg-
ative test result for an individual with a mutation-specific
test could result.
Even among families with founder mutations, there appear
to be differences in age of onset of cancer and in the type
of cancers that develop [28,37–39]. This suggests that
there are both genetic and lifestyle factors that modify
penetrance of BRCA1 and BRCA2. By studying a cohort
of individuals with the same mutation, one may be able to
distinguish factors that affecting penetrance, because
there will not be a confounding effect from genotype–phe-
notype correlations from location of the BRCA1/BRCA2
mutation in the individual. Once a risk factor is identified in
one subgroup of mutation carriers it would need to be
tested across other mutation carriers. Subsequently, itwould need to be tested in a population-based case–
control study, in order to determine how important the risk
factor is in the general population.
Other genes
BRCA1 and  BRCA2 mutations are certainly important
determinants of risk for breast and/or ovarian cancers, but
they are not the only ones. Many women, who have a
family history of breast and/or ovarian cancer and do not
have a BRCA1 or BRCA2 mutation, may have a mutation
in undiscovered genes. After accounting for BRCA1 and
BRCA2, Peto et al [12] suggested that there are several
other genes, possibly of lower risk, that account for a pro-
portion of breast cancers. This complexity makes localizing
additional genes problematic. Studying families identified
from populations in which there are likely to be founder
mutations may be extremely useful for localizing additional
genes. For example, in Iceland researchers may have been
able to localize BRCA2 by studying male breast cancer
cases from high-risk families and looking for regions of the
genome with excess sharing. Researchers have sug-
gested studying high-risk Ashkenazi Jewish breast cancer
families that do not have a BRCA1 or BRCA2 mutation in
order to localize BRCA3. Localization will be promoted by
minimizing the effects of genetic heterogeneity.
Conclusion
Founder mutations allow for focused scientific studies of
penetrance, expression, and genetic and environmental
modifiers of risk. The results from these studies may be
very useful for understanding the role that these genes
play in the incidence of breast cancer in order to target
genetic testing, to provide individual risk assessment, and
to design better therapeutic strategies. Localization
studies to find BRCA3, using founder populations, may be
more successful than traditional linkage studies, which
have not yet yielded positive localization results. These
types of studies, utilizing founder populations and muta-
tions, are not unique to breast cancer genetics, and are
being used successfully to understand other diseases.
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